Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-10-17
2006-10-17
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S192100, C424S208100
Reexamination Certificate
active
07122190
ABSTRACT:
The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAIgp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4659669 (1987-04-01), Kleid et al.
patent: 4707358 (1987-11-01), Kieff et al.
patent: 4761470 (1988-08-01), Emini et al.
patent: 5057211 (1991-10-01), Baummer
patent: 5116725 (1992-05-01), Vaughan et al.
patent: 5141867 (1992-08-01), Ivanoff et al.
patent: 5156949 (1992-10-01), Luciw et al.
patent: 5444044 (1995-08-01), Jiang et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5840843 (1998-11-01), Jiang et al.
patent: 5853978 (1998-12-01), Berman et al.
patent: 5876969 (1999-03-01), Fleer et al.
patent: 6001977 (1999-12-01), Chang et al.
patent: 6017536 (2000-01-01), Barney et al.
patent: 6025325 (2000-02-01), Compfield et al.
patent: 6248574 (2001-06-01), Shaffermann
patent: 6261564 (2001-07-01), Alizon et al.
patent: 6440656 (2002-08-01), Bolognesi et al.
patent: 6440657 (2002-08-01), Montangnier et al.
patent: 6479055 (2002-11-01), Bolognesi et al.
patent: 6531276 (2003-03-01), Luciw et al.
patent: 6610476 (2003-08-01), Chang et al.
patent: 6858712 (2005-02-01), Chang et al.
patent: 1341476 (2005-03-01), None
patent: 0 323 157 (1988-12-01), None
patent: 0 362 927 (1990-04-01), None
patent: 0 181 150 (2003-03-01), None
patent: 2677346 (1992-12-01), None
patent: WO 86/01535 (1986-03-01), None
patent: WO 86/02383 (1986-04-01), None
patent: WO 86/04336 (1986-07-01), None
patent: WO 88/08429 (1988-11-01), None
patent: WO 89/02935 (1989-04-01), None
patent: WO 90/07119 (1990-06-01), None
patent: WO 91/09872 (1991-07-01), None
patent: WO 92/00997 (1992-01-01), None
patent: WO 92/22654 (1992-12-01), None
patent: WO 93/14207 (1993-07-01), None
Chen, C.-H., et al., 1995, “A Molecular Clasp in the Human Immunodeficiency Virus (HIV) Type 1 TM Protein Determines the Anti-HIV Activity of gp41 Derivatives: Implication for Viral Fusion”, J. Virol. 69(6):3771-3777.
Louis, J. M., et al., 1991, “Autoprocessing of the HIV-1 Protease Using Purified Wild-type and Mutated Fusion Proteins Expressed at High Levels inEscherichia coli”, Eur. J. Biochem. 199:361-369.
Paige, A. G., et al., 1995, “Prolonged Circulation of Recombinant Human Granulocyte Colony Stimulating Factor by Covalent Linkage to Albumin Through a Heterobifunctional Polyethylene Glycol”, Pharm. Res. 12(12):1883-1888.
U.S. Appl. No. 08/484,223, filed Jun. 7, 1995, Barney et al.
Wild et al., 1992, A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition, Proc. Natl. Acad. Sci USA 89:10537-10541.
Mitsuya et al., 1991, Targeted therapy of human immunodeficiency virus-related disease, FASEB J. 5:2369-2381.
Hammarskjold and Rekosh, 1989, The molecular biology of the human immunodeficiency virus, Biochem. Biophys. Acta 989:269-280.
Guyader et al., 1987, Genome organization and transactivation of the human immunodeficiency virus type 2, Nature 326:662-669.
Clavel et al., 1986, Isolation of a new human retrovirus from West African patients with AIDS, Science 233:343-346.
Maddon et al., 1986, The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain, Cell 47:333-348.
McDougal et al., 1986, Binding of HTLV-III/LAV to T4+T cells by a complex of the 110k viral protein and the T4 molecule, Science 231:382-385.
Barin et al., 1985, Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients, Science 228:1094-1096.
Dalgleish et al., 1984, The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus, Nature 312:763-767.
Gallo et al., 1984, Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS, Science 224:500-503.
Klatzmann et al., 1984, T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LA V, Nature 312:767-768.
Teich et al., 1984, Pathogenesis of lentivirus, in “RNA Tumor Viruses” Weiss et al., eds., CSH-Press, pp. 949-956.
Barre-Sinoussi et al., 1983, Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS), Science 220:868-870.
Suzuki et al., 1995, “Viral Interleukin 10 (IL-10), the Human Herpes Virus 4 Cellular IL-10 Homologue, Induces Local Anergy to Allogenic and Syngeneic Tumors”, J of Experimental Medicine 182:477-486.
Wild et al., 1994, “Propensity for a Leucine Zipper-Like Domain of Human Immunodeficiency Virus Type 1 gp41 to Form Oligomers Correlates With a Role in Virus-Induced Fusion Rather Than Assembly of the Glycoprotein Complex”, Proc. Natl. Acad. Sci. USA 91:12676-80.
Collins et al., 1984, “Nucleotide Sequence of the Gene Encoding the Fusion (F) Glycoprotein of Human Respiratory Syncytial Virus”, Proc. Natl. Acad. Sci. USA 81:7683-87.
Smith et al., 1987, “Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen”, Science 238:1704-1707.
Erickson et al., 1990, “Design, Activity, and 2.8 Å Crystal Structure of a C2 Symmetric Inhibitor Complexed to HIV-1 Protease”, Science 249:527-533.
Daar et al., 1990, “High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates”, Proc. Natl. Acad. Sci. USA 87:6574-6579.
Lazinski et al., 1993, “Relating Structure to Function in the Hepatitis Delta Virus Antigen”, J of Virology 67:2672-80.
Wang et al., 1993, “Ion Channel Activity of Influenza A Virus M2 Protein: Characterization of the Amantidine Block”, J of Virology 67:5585-94.
Bousse et al., 1994, “Regions on the Hemagglutinin-Neuraminidasc Proteins of Human Parainfluenza Virus Type-1 and Sendai Virus Important for Membrane Fusion”, Virology 204:506-514.
Staden, 1990, “Searching for Patterns in Protein and Nucleic Acid Sequences”, Meth. Enzymol. 183:193-211.
Staden, 1994, “Using Patterns to Analyze Protein Sequences”, Chapter 13 in: Methods in Molecular Biology, vol. 25, Griffin et al., eds., Humana Press, Inc., Totowa, NJ, p. 141-154.
Staden, 1994, “Searching for Motifs in Protein Sequences”, Chapter 12 in: Methods in Molecular Biology, vol. 25, Griffin et al., eds., Humana Press, Inc., Totowa, NJ, p. 131-139.
Bousse et al. 1995, “A single amino acid changes enhances the fusion promotion activity of human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein”. Virology. 209(2):654-7.
Geysen et al. 1988, Cognitive features of continuous antigenic determinants. J. Molec. Recog. 1:33-41.
Wildner et al. 1997 Database screening for molecular mimicry. Immunol Today. 18(5):252.
Roudier J. 1997, Response to Wildner et al. and Burns et al. Immunol. Today; 18(5):252.
Hall CB. 1994, Prospects for a respiratory syncytial virus vaccine. Science. 2;265(5177):1393-4. Review.
Toms GL. 1995, Respiratory syncytial virus—how soon will we have a vaccine? Arch Dis Child. 72(1):1-3.
Benet et al. 1990, “Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination” inThe Pharmacological Basis of Therapeutics, Goodman et al., eds., Pergammon Press, New York, pp. 3-32.
Flexner C. and Hendrix, C. “Pharmacology of anti-retroviral agents”. InAIDS: Biology, Diagnosis, Treatment and Prevention.4thEdition, DeVita et al. Eds., Lippincott-Raven Publishers, pp. 479-493.
Yarchoan et al. 1992, Correlations between the in vitro and in vivo activity of anti-HIV agents: implications for future drug development. J Enzyme Inhib.;6(1):99-111. Review.
Gait et
Barney Shawn O'Lin
Bolognesi Dani Paul
Lambert Dennis Michael
Langlois Alphonse J.
Matthews Thomas James
Duke University
Jones Day
Parkin Jeffrey S.
LandOfFree
Fusion proteins comprising DP-178 and other viral fusion... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fusion proteins comprising DP-178 and other viral fusion..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion proteins comprising DP-178 and other viral fusion... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3704213